About Lucier Pharmaceuticals

To address unmet medical needs, Lucier Pharmaceuticals is developing novel drugs toward effectively managing microvascular diseases.

Our drug candidates are based on novel scientifc findings from Texas A&M University, which support one patent (WO2024238454) application.


Pipeline

Preclincial development
LU-1001: injectable small molecular inhibitor to improve the diagnosis of coroanry microvascular dysfunction/disease (CMD).
LU-1002: oral small molecular inhibitor for treating microvascular diseases.

Meet Our Team

Guangrong Lu, MBBS.

Co-inventor

Founder and CEO

Lih Kuo, PhD.

Co-inventor

Regents Professor, Scientific Advisor

E.L. Berryman

Reg. Toxicologist

Pre-clinical Development Advisor

Lee Schalop, MD.

Angel Investor and Entrepreneur

Business Advisor

Some videos by medical professionals maybe helpful for you to better understand microvascular dysfunction

https://www.youtube.com/watch?v=0Hx51knjCSg
https://www.youtube.com/watch?v=wOcsbpOyU38
https://www.youtube.com/watch?v=kXBognpmYlg